Last update 01 Nov 2024

EML4-ALK x ALK x MST1R x c-Met

Basic Info

Related Targets
EML4-ALKALKMST1R[+1]

Related

1
Drugs associated with EML4-ALK x ALK x MST1R x c-Met
Crizotinib
Target
ALK x EML4-ALK x MST1R x c-Met
Mechanism
ALK inhibitors [+3]
Active Org.
Pfizer Europe MA EEIG [+3]
Originator Org.
Pfizer Global Manufacturing China
Active Indication
ALK-Positive Inflammatory Myofibroblastic Tumor [+16]
Inactive Indication
Advanced cancer [+25]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date26 Aug 2011
134
Clinical Trials associated with EML4-ALK x ALK x MST1R x c-Met
NCT06563999 / Not yet recruitingPhase 2IIT
Neoadjuvant Umbrella Trial Directed by Next Generation Sequencing for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations (Without EGFR Sensitizing Mutations)
100 Clinical Results associated with EML4-ALK x ALK x MST1R x c-Met
Login to view more data
100 Translational Medicine associated with EML4-ALK x ALK x MST1R x c-Met
Login to view more data
0 Patents (Medical) associated with EML4-ALK x ALK x MST1R x c-Met
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free